The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient populationOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.